지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한백신학회 Clinical and Experimental Vaccine Research Clinical and Experimental Vaccine Research Vol.10 No.2
- 발행연도
- 2021.1
- 수록면
- 151 - 153 (3page)
이용수
초록· 키워드
오류제보하기
The current coronavirus disease 2019 (COVID-19) outbreak has created a huge demand for rapid and high-volume vaccine manufacturing. Several new platform technologies and traditional manufacturing approaches are being used to meet this demand. Among them, the mRNA vaccine platform technology holds great promise for obtaining an emergency use authorization to facilitate immunization against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which causes the respiratory illness COVID-19. However, this is a new technology, which means that there is significant uncertainty about possible production at a large scale and speed. Vaccines of mRNA work by providing our cells with the genetic code to make viral proteins. Once proteins that do not cause any disease are produced, the body triggers an immune response against the virus, allowing them to develop immunity. mRNA can be used to make any protein theoretically. Still, it is much easier to produce than the proteins themselves or the inactivated and attenuated versions of viruses commonly used in vaccines, which makes this technique attractive, says mRNA specialist Norbert Pardi, at the University of Pennsylvania.
목차
등록된 정보가 없습니다.
참고문헌 (7)
참고문헌 신청
Vaccine Adverse Event Reporting System
Broyles AD / 2020 / Practical guidance for the evaluation and management of drug hypersensitivity : specific drugs / J Allergy Clin Immunol Pract 8(9S):S16~S116
Yang Q / 2015 / Anti-PEG immunity: emergence, characteristics, and unaddressed questions / Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:655~677
Probst J / 2007 / Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent / Gene Ther 14:1175~1180
Reuters / Lonza aims to make ingredients for 400 million doses of Moderna’s COVID vaccine annually / Reuters
Broyles AD / 2020 / Practical guidance for the evaluation and management of drug hypersensitivity : specific drugs / J Allergy Clin Immunol Pract 8(9S):S16~S116
Yang Q / 2015 / Anti-PEG immunity: emergence, characteristics, and unaddressed questions / Wiley Interdiscip Rev Nanomed Nanobiotechnol 7:655~677
Probst J / 2007 / Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent / Gene Ther 14:1175~1180
Reuters / Lonza aims to make ingredients for 400 million doses of Moderna’s COVID vaccine annually / Reuters
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review
Journal of Yeungnam Medical Science
2022 .04
-
Review of COVID-19 Vaccines and Their Evidence in Older Adults
Annals of geriatric medicine and research
2021 .01
-
Advancements in Cancer Immunotherapy: The Evolution and Future of mRNA and DNA Vaccine Technologies
대한의생명과학회지
2025 .03
-
Non-clinical safety assessment for mRNA vaccine in mouse model
한국실험동물학회 학술발표대회 논문집
2025 .02
-
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic
Immune Network
2021 .02
-
Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea
Journal of Korean Medical Science
2024 .01
-
Comparison of COVID-19 Vaccines Introduced in Korea
대한의생명과학회지
2022 .06
-
Shingles and mRNA COVID?19 vaccine
Clinical and Experimental Vaccine Research
2021 .09
-
Should the COVID-19 Vaccine be Administered Simultaneously with Other Vaccines?
Infection and Chemotherapy
2021 .09
-
Exploring the experience of developing COVID-19 vaccines in Iran
Clinical and Experimental Vaccine Research
2023 .01
-
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Journal of Korean Medical Science
2021 .01
-
항공종사자와 코로나바이러스감염증-19 백신 예방 접종
항공우주의학회지
2021 .04
-
Adverse events and preventive measures related to COVID-19 vaccines
Clinical and Experimental Emergency Medicine
2021 .09
-
Inside the story about the research and development of COVID-19 vaccines
Clinical and Experimental Vaccine Research
2021 .01
-
Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?
Infection and Chemotherapy
2021 .12
-
Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea
Journal of Korean Medical Science
2024 .09
-
Factors influencing acceptance of the COVID-19 vaccine in Malaysia: a web-based survey
Osong Public Health and Research Persptectives
2021 .12
-
Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022
Journal of Korean Medical Science
2023 .05
-
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages
Immune Network
2021 .02
-
Adult-onset Still’s Disease after BNT162b2 mRNA COVID-19 Vaccine
Journal of Korean Medical Science
2021 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0